Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations

• Published in: Quality of life research Vol. 21; no. 6; pp. 975 - 981
• Main Authors: Eaton, Thomas A., Comer, Sandra D., Revicki, Dennis A., Trudeau, Jeremiah J., van Inwegen, Richard G., Stauffer, Joseph W., Katz, Nathaniel P.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 01.08.2012; Springer Netherlands; Springer Nature B.V
• Subjects: Analgesics; Analgesics, Opioid - therapeutic use; Brief Communication; CLINICAL AND POLICY APPLICATIONS; Controlled substances; Datasets; Dosage; Drug abuse; Drug dosages; Heroin; Humans; Laboratories; Liability; Medication administration; Medicine; Medicine & Public Health; Methods; Morphine; Naltrexone - therapeutic use; Narcotics; Opioid analgesics; Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - psychology; Pain measurement scales; Placebos; Product development; Public Health; Quality of Life Research; Ratings & rankings; Retention; Sociology; Standard deviation; Substance abuse treatment; Opioid; Drug high; Morphine; Abuse liability; Analgesics; Drug formulations

Purpose This study determined how the magnitude of change in positive subjective responses predicts clinical outcome in a treatment setting. Specifically, we attempted to define what constitutes a clinically important difference (CID) in subjective responses. Methods A 100-mm visual analog scale (VA...